SRNE vs. COEP, SNTI, GENE, IKT, ONVO, BCDA, PMCB, CELZ, CHRO, and SRZN
Should you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Coeptis Therapeutics (COEP), Senti Biosciences (SNTI), Genetic Technologies (GENE), Inhibikase Therapeutics (IKT), Organovo (ONVO), BioCardia (BCDA), PharmaCyte Biotech (PMCB), Creative Medical Technology (CELZ), Chromocell Therapeutics (CHRO), and Surrozen (SRZN). These companies are all part of the "biological products, except diagnostic" industry.
Sorrento Therapeutics (NASDAQ:SRNE) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.
Coeptis Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 782.35%. Given Coeptis Therapeutics' higher possible upside, analysts plainly believe Coeptis Therapeutics is more favorable than Sorrento Therapeutics.
Sorrento Therapeutics received 605 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Coeptis Therapeutics an outperform vote while only 71.18% of users gave Sorrento Therapeutics an outperform vote.
Sorrento Therapeutics' return on equity of 0.00% beat Coeptis Therapeutics' return on equity.
In the previous week, Coeptis Therapeutics had 1 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 2 mentions for Coeptis Therapeutics and 1 mentions for Sorrento Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.00 equaled Coeptis Therapeutics'average media sentiment score.
Sorrento Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.88, meaning that its share price is 188% less volatile than the S&P 500.
Coeptis Therapeutics has lower revenue, but higher earnings than Sorrento Therapeutics.
0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 21.5% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Coeptis Therapeutics beats Sorrento Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Sorrento Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sorrento Therapeutics Competitors List
Related Companies and Tools
